The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...
The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...
The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...
According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or...
The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...
The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L...
Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation...
According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease...
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...
The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and SCO-240,...
The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs,...
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new...